|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM309279593 |
| 003 |
DE-627 |
| 005 |
20250227051728.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108445
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1030.xml
|
| 035 |
|
|
|a (DE-627)NLM309279593
|
| 035 |
|
|
|a (NLM)32344016
|
| 035 |
|
|
|a (PII)S1521-6616(20)30128-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Frangou, Eleni
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Update on the cellular and molecular aspects of lupus nephritis
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.02.2021
|
| 500 |
|
|
|a Date Revised 01.02.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Recent progress has highlighted the involvement of a variety of innate and adaptive immune cells in lupus nephritis. These include activated neutrophils producing extracellular chromatin traps that induce type I interferon production and endothelial injury, metabolically-rewired IL-17-producing T-cells causing tissue inflammation, follicular and extra-follicular helper T-cells promoting the maturation of autoantibody-producing B-cells that may also sustain the formation of germinal centers, and alternatively activated monocytes/macrophages participating in tissue repair and remodeling. The role of resident cells such as podocytes and tubular epithelial cells is increasingly recognized in regulating the local immune responses and determining the kidney function and integrity. These findings are corroborated by advanced, high-throughput genomic studies, which have revealed an unprecedented amount of data highlighting the molecular heterogeneity of immune and non-immune cells implicated in lupus kidney disease. Importantly, this research has led to the discovery of putative pathogenic pathways, enabling the rationale design of novel treatments
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Autoantibodies
|
| 650 |
|
4 |
|a Cytokines
|
| 650 |
|
4 |
|a Macrophages
|
| 650 |
|
4 |
|a Podocytes
|
| 650 |
|
4 |
|a RNA sequencing
|
| 650 |
|
4 |
|a Renal tubular epithelial cells
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 700 |
1 |
|
|a Georgakis, Spyros
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bertsias, George
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 216(2020) vom: 01. Juli, Seite 108445
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:216
|g year:2020
|g day:01
|g month:07
|g pages:108445
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108445
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 216
|j 2020
|b 01
|c 07
|h 108445
|